ClinicalTrials.gg
RecruitingNCT06435429Updated Feb 10, 2026

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

A Phase 3 interventional study of Zanidatamab and Trastuzumab in Metastatic HER2-positive Breast Cancer, sponsored by Jazz Pharmaceuticals. Recruiting at 166 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The efficacy and safety of zanidatamab in combination with physician's choice of chemotherapy compared with trastuzumab in combination with physician's choice of chemotherapy will be evaluated for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.

Read the detailed description

Zanidatamab, as a monotherapy or in combination with other antineoplastic agents, has shown clinically meaningful efficacy against multiple HER2-positive advanced/metastatic tumors, including in patients with metastatic breast cancer (mBC). Zanidatamab may offer a viable treatment option for patients with metastatic HER2-positive breast cancer.

The primary objective of the study is to compare the efficacy of zanidatamab plus chemotherapy versus trastuzumab plus chemotherapy. The secondary objectives of the study will include further comparing the efficacy, safety and tolerability, patient-reported tolerability, and patient-reported physical functioning of zanidatamab plus chemotherapy versus trastuzumab plus chemotherapy. The pharmacokinetics and immunogenicity of zanidatamab in combination with chemotherapy will also be evaluated.

02

Conditions studied

  • Metastatic HER2-positive Breast Cancer

Browse trials for

Keywords

  • Zanidatamab
  • Trastuzumab
  • Metastatic HER2-positive breast cancer
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's planned enrollment of 550 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.

Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  1. Is 18 years of age or of the legal adult age per local standard at the time of signing the .
  2. Has confirmed -positive breast cancer according to ASCO-CAP Guidelines as evaluated by a sponsor-designated central laboratory
  3. Participants with unresectable or HER2 positive breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment.
  4. Must have received at least 2 lines of HER2-directed therapy for their metastatic disease.

    1. Prior HER2-targeted or adjuvant therapy that resulted in relapse within 6 months of the completion of therapy will be considered a for metastatic disease.
    2. Based on the physician's choice, participants' eligibility, and institutional and local guidelines, participants may also have received post-T-DXd therapy, for example, a tucatinib-based regimen and/or T-DM1.
    3. Participants must not have received more than 4 lines of HER2-directed therapy in the metastatic setting.
  5. Has per version 1.1.
  6. Is eligible to receive one of the chemotherapy options listed in the physician's choice of chemotherapy (eribulin, gemcitabine, vinorelbine, or capecitabine).
  7. Participants with history of treated or clinically inactive are eligible as specified in the protocol.
  8. Has a of at least 6 months, in the opinion of the investigator.
  9. Has adequate hematologic parameters as defined in the protocol.
  10. Has adequate hepatic function as specified in the protocol.
  11. Has ≥ 50 mL/minute as calculated per local institutional guidelines.
  12. Has ≥ 50% as determined by either echocardiogram or MUGA obtained within 4 weeks before the first dose of study intervention.
  13. Has performance status of 0 or 1.
  14. Participant agrees to the following based on sex assigned at birth.

    1. Male participants:

      Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 7 months after the last dose of study intervention or the period for the combination chemotherapy of choice per local guidance/standard practice:

      • Refrain from donating fresh unwashed semen.
      • Use contraception as follows as specified in the protocol
    2. Female participants:

      • A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:

        • Is a women of nonchildbearing potential OR
        • Is a woman of (WOCBP) and using a contraceptive method that is highly effective (with a failure rate of \< 1% per year), with low user dependency during the study intervention period and for at least 7 months after the last dose of study intervention.
      • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 3 days before the first dose of study intervention.
      • Additional requirements for pregnancy testing during and after study intervention are provided in the protocol.
      • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  15. Is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the protocol.

Participants are excluded from the study if any of the following criteria apply:

Medical Conditions

  1. Has clinically confirmed , in the opinion of the investigator.
  2. Has uncontrolled or significant cardiovascular disease.
  3. Has toxicity related to prior cancer therapy that has not resolved to ≤ Grade 1, with exceptions as stated in the protocol.
  4. Has uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
  5. Has an infection with -1 or HIV-2, with the exception of participants with well-controlled HIV.
  6. Has active or C infection.
  7. Has an active SARS-CoV-2 infection. Participants with prior infection that has resolved per local institutions' requirements and screening guidance are eligible.
  8. Has a history of life-threatening to monoclonal antibodies or to recombinant proteins or in the drug formulation of zanidatamab.
  9. Is unable to receive trastuzumab treatment due to medical .
  10. Has any serious underlying medical or psychiatric condition that would impair the ability of the participant to receive or tolerate the planned treatment at the site.
  11. Has any condition that would prevent treatment with the physician's choice of chemotherapy.
  12. Has any issue or condition that in the opinion of the investigator would contraindicate the participant's participation in the study or confound the results of the study.

    Prior/Concomitant Therapy

  13. Has a history of prior allogeneic bone marrow, stem cell, or solid organ transplantation.
  14. The for prior anticancer therapies before randomization as specified in the protocol.
  15. Has a history of trauma or major surgery within 4 weeks prior to randomization.

    Other Exclusions

  16. Has a known hypersensitivity to any components of the study drugs, including chemotherapy.
  17. Female participants who are breastfeeding or pregnant, and female and male participants planning a pregnancy.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Zanidatamab plus physician's choice of chemotherapy

    Participants with HER2-positive metastatic breast cancer (mBC) who have progressed on, or are intolerant to, previous T-DXd treatment will be randomized to receive intravenous infusion of zanidatamab plus physician's choice of chemotherapy (eribulin, or vinorelbine, or gemcitabine, or capecitabine).

    Drug: Zanidatamab · Drug: Eribulin · Drug: Vinorelbine · Drug: Gemcitabine · Drug: Capecitabine

  • Active comparator
    Trastuzumab plus physician's choice of chemotherapy

    Participants with HER2-positive metastatic breast cancer (mBC) who have progressed on, or are intolerant to, previous T-DXd treatment will be randomized to receive intravenous infusion of trastuzumab plus physician's choice of chemotherapy (eribulin, or gemcitabine, or vinorelbine, or capecitabine).

    Drug: Trastuzumab · Drug: Eribulin · Drug: Vinorelbine · Drug: Gemcitabine · Drug: Capecitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Per RECIST Version 1.1 As Assessed by Blinded Independent Central Review (BICR)

    PFS is defined as the time in months from randomization to the date of first documented disease progression (as assessed by BICR according to RECIST v1.1) or death from any cause, whichever occurs first.

    Time frame: Until disease progression or death, up to approximately 44 months

Secondary outcomes

  1. Overall Survival (OS)

    OS is defined as the time in months from randomization to the date of death due to any cause.

    Time frame: Until death, up to approximately 80 months

  2. Confirmed Objective Response Rate (ORR) Per RECIST Version 1.1, As Assessed by BICR

    The BICR-assessed confirmed ORR is defined as the proportion of participants who had a best overall response of BICR-assessed Complete Response (CR) or Partial Response (PR) after randomization.

    Time frame: Until disease progression or death, up to approximately 44 months

  3. Duration of Response (DOR) Per RECIST Version 1.1, As Assessed by BICR

    BICR-assessed DOR is defined as the time in months from the first objective response (CR or PR) that is subsequently confirmed to documented progressive disease (PD) as assessed by BICR per RECIST v1.1 or death from any cause.

    Time frame: Until disease progression or death, up to approximately 44 months

  4. PFS Per RECIST Version 1.1, As Assessed By Investigator

    Investigator-assessed PFS is defined as the time in months from randomization to the date of first documented disease progression (as assessed by investigator according to RECIST v1.1) or death from any cause, whichever occurs first

    Time frame: Until disease progression or death, up to approximately 44 months

  5. Confirmed ORR Per RECIST Version 1.1, As Assessed By Investigator

    The investigator-assessed confirmed ORR is defined as the proportion of participants who had a best overall response of investigator-assessed confirmed CR or PR after randomization.

    Time frame: Until disease progression or death, up to approximately 44 months

  6. DOR Per RECIST Version 1.1, As Assessed By Investigator

    Investigator-assessed DOR is defined as the time in months from the first objective response (CR or PR) that is subsequently confirmed to documented PD as assessed by the investigator per RECIST v1.1 or death from any cause.

    Time frame: Until disease progression or death, up to approximately 44 months

  7. Number of Participants Reporting Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events As Graded by NCI CTCAE Version 5.0

    Time frame: Up to approximately 44 months

  8. Number of Participants With Dose Reductions

    Time frame: Up to approximately 44 months

  9. Number of Participants Discontinuing Study Treatment Due to TEAEs

    Time frame: Up to approximately 44 months

  10. Serum Concentrations of Zanidatamab

    Time frame: Up to approximately 44 months

  11. Number of Participants Positive for Anti-drug Antibodies to Zanidatamab

    Time frame: Up to approximately 44 months

  12. Proportion of All Treated Participants, As Treated, Reporting Symptomatic Adverse Events While On Treatment Based on Patient-reported Outcome-Common Terminology Criteria for AEs and European Organisation for Research and Treatment of Cancer Item Library

    Time frame: Up to approximately 44 months

  13. Proportion of All Treated Participants, As Treated, Reporting Overall Side-effect Bother on the Functional Assessment of Chronic Illness Therapy General Physical Item 5 (FACIT-GP5)

    The Functional Assessment of Chronic Illness Therapy (FACIT) GP5 Item score ranges from 0 (Not at all) to 4 (Very Much), where higher scores reflect greater bother from treatment side effects.

    Time frame: Up to approximately 44 months

  14. Proportion of Treated Participants, As Treated, With Maintained or Improved Physical Function While On Treatment Based On The Physical Functioning Subscale of the EORTC Quality of Life Questionnaire Core Module (EORTC QLQ-C30)

    The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core Module Physical Functioning score ranges from 0 to 100, where higher scores reflect better functioning.

    Time frame: Up to approximately 44 months

07

Study locations

163 of 166 sites recruiting
  • Mayo Clinic Scottsdale - PPDS
    Phoenix, Arizona 85054, United States
    Recruiting
  • Arizona Oncology Tucson - Wilmot
    Tucson, Arizona 85711, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • University of Arizona Cancer Center
    Tucson, Arizona 85719, United States
    Recruiting
  • The Oncology Institute Of Hope And Innovation
    Cerritos, California 90703, United States
    Recruiting
  • Los Angeles Hematology Oncology Medical Group Glendale
    Glendale, California 91204, United States
    Recruiting
  • USC-Norris Comprehensive Cancer Center - Investigational Drug Service IDS
    Los Angeles, California 90033, United States
    Recruiting
  • UCSF at Mission Bay MB
    San Francisco, California 94158, United States
    Recruiting
  • University of Colorado-Cancer Center-PPDS
    Aurora, Colorado 80045-2517, United States
    Recruiting
  • Rocky Mountain Cancer Centers
    Denver, Colorado 80218, United States
    Recruiting
  • Medstar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
    Recruiting
  • Washington Cancer Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Florida Cancer Specialists Research South
    Fort Myers, Florida 33901, United States
    Recruiting
  • Mayo Clinic Jacksonville - PPDS
    Jacksonville, Florida 32224, United States
    Recruiting
  • Florida Cancer Specialists Research North
    St. Petersburg, Florida 33705, United States
    Recruiting
  • Florida Cancer Specialists Research East
    West Palm Beach, Florida 33401, United States
    Recruiting
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215-5418, United States
    Recruiting
  • Minnesota Oncology Hematology
    Coon Rapids, Minnesota 55433, United States
    Recruiting
  • Mayo Clinic - PPDS
    Rochester, Minnesota 55905, United States
    Recruiting
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111, United States
    Recruiting
  • Hackensack Meridian Health
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • Memorial Sloan Kettering
    Long Island City, New York 11101, United States
    Recruiting
  • Perlmutter Cancer Center 160 E 34th St
    New York, New York 10016-4744, United States
    Recruiting
  • The Mount Sinai Hospital
    New York, New York 10029, United States
    Recruiting
  • Columbia University Medical Center 161 Fort Washington
    New York, New York 10032-3729, United States
    Recruiting
  • Messino Cancer Center
    Asheville, North Carolina 28806, United States
    Recruiting
  • Duke Cancer Institute
    Durham, North Carolina 27710-2000, United States
    Recruiting
  • UNC Central Investigational Drug Services
    Morrisville, North Carolina 27560, United States
    Recruiting
  • Oncology Hematology Care (OHC)
    Cincinnati, Ohio 45226, United States
    Recruiting
  • University Hospitals Cleveland Medical Center 11100 Euclid Ave
    Cleveland, Ohio 44106-1716, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Abramson Cancer Center of The University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
    Recruiting
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
    Recruiting
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
    Recruiting
  • Texas Oncology - Fort Worth
    Fort Worth, Texas 76104, United States
    Recruiting
  • U.T. MD Anderson Cancer Center, Investigational Pharmacy Services
    Houston, Texas 77030, United States
    Recruiting
  • Millennium Research and Clinical Development
    Houston, Texas 77090, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Maryland Oncology Hematology Healing Way - USOR
    Irving, Texas 75063, United States
    Recruiting
  • Medical Oncology Hematology Consultants
    Irving, Texas 75063, United States
    Recruiting
  • Nexus Health
    Irving, Texas 75063, United States
    Recruiting
  • Sansum Clinic 540 W - USOR
    Irving, Texas 75063, United States
    Recruiting
  • Texas Oncology Gulf Coast
    Irving, Texas 75063, United States
    Recruiting
  • Texas Oncology West
    Irving, Texas 75063, United States
    Recruiting
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
    Recruiting
  • Virginia Oncology Associates, Sentara Health
    Norfolk, Virginia 23502, United States
    Recruiting
  • Blue Ridge Cancer Care
    Roanoke, Virginia 24014, United States
    Recruiting
  • Fred Hutchinson Cancer Center
    Seattle, Washington 98109, United States
    Recruiting
  • Froedtert and The Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
    Recruiting
  • Sunshine Coast University Private Hospital
    Birtinya, Queensland 4575, Australia
    Recruiting
  • Box Hill Hospital
    Melbourne, Victoria 3128, Australia
    Recruiting
  • Peninsula and South Eastern Haematology and Oncology Group
    Mount Waverly, Victoria 3149, Australia
    Recruiting
  • HPS Pharmacies - Adelaide
    Adelaide, 5000, Australia
    Recruiting
  • The Kinghorn Cancer Centre
    Mount Kuring-Gai, 2080, Australia
    Recruiting
  • St John of God Hospital Subiaco
    Subiaco, 6008, Australia
    Recruiting
  • Medizinische Universitat Innsbruck
    Innsbruck, 6020, Austria
    Recruiting
  • Ordensklinikum Barmherzige Schwestern
    Linz, 4010, Austria
    Recruiting
  • Medizinische Universitat Wien
    Vienna, 1090, Austria
    Recruiting
  • Klinikum Wels-Grieskirchen GmbH - Abteilung für Innere Medizin IV
    Wels, 4600, Austria
    Recruiting
  • Institute Jules Bordet
    Anderlecht, 1070, Belgium
    Recruiting
  • UZ Antwerpen
    Edegem, 2650, Belgium
    Recruiting
  • Grand Hôpital de Charleroi
    Gilly, 6060, Belgium
    Recruiting
  • CHU UCL Namur - Site Sainte-Elisabeth
    Namur, 5000, Belgium
    Recruiting
  • AZ Delta- Campus Rumbeke
    Roeselare, 8800, Belgium
    Recruiting
  • Hospital Nossa Senhora Da Conceição
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
    Recruiting
  • IEPE Unimed Sorocaba
    Sorocaba, São Paulo 18060-105, Brazil
    Recruiting
  • DASA Hospital Brasilia
    Brasília, 71.635-610, Brazil
    Recruiting
  • Centro Regional Integrado de Oncologia
    Ceará, 60336-232, Brazil
    Recruiting
  • Catarina Pesquisa Clinica
    Itajaí, 88301-220, Brazil
    Recruiting
  • Irmandade Da Santa Casa de Misericordia de Porto Alegre
    Portalegre, 90050-170, Brazil
    Recruiting
  • Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul PUCRS
    Porto Alegre, 90610-001, Brazil
    Recruiting
  • Real Hospital Portugues de Beneficiencia Em Pernambuco
    Recife, 52.010-075, Brazil
    Recruiting
  • Nucleo de Oncologia Da Bahia
    Salvador, 40.170-070, Brazil
    Recruiting
  • Ceon Pesquisas Ltda
    São Caetano do Sul, 09541-270, Brazil
    Recruiting
  • Hospital Beneficiencia Portuguesa
    São Paulo, 01323-030, Brazil
    Recruiting
  • Onco Star Sp Oncologia LTDA
    São Paulo, 04062-001, Brazil
    Recruiting
  • Jewish General Hospital
    Montreal, H3T 1E2, Canada
    Recruiting
  • The Ottawa Hospital Cancer Centre
    Ottawa, K1H 8L6, Canada
    Recruiting
  • CHU de Québec Université Laval Hôpital du Saint Sacrement
    Québec, G1S 4L8, Canada
    Recruiting
  • Sunnybrook Research Institute
    Toronto, M4N 3M5, Canada
    Recruiting
  • BC Cancer-Vancouver Center
    Vancouver, V5Z 4E6, Canada
    Recruiting
  • Institut Bergonie
    Bordeaux, 33076, France
    Recruiting
  • Centre François Baclesse
    Caen, 14000, France
    Recruiting
  • Centre Georges François Leclerc
    Dijon, 21000, France
    Recruiting
  • Pharmacie Centre de Cancerologie de la Sarthe
    Le Mans, 72000, France
    Recruiting
  • Centre Oscar Lambret
    Lille, 59020, France
    Recruiting
  • AP HM Hopital de La Timone
    Marseille, 13005, France
    Recruiting
  • Institut Paoli Calmettes
    Marseille, 13009, France
    Recruiting
  • Pharmacie ICM Val d'Aurelle
    Montpellier, 34298, France
    Recruiting
  • ICANS - Institut de cancérologie Strasbourg Europe
    Strasbourg, 67000, France
    Recruiting
  • Oncopôle Claudius Regaud Pharmacie
    Toulouse, 31059, France
    Recruiting
  • Gustave Roussy
    Villejuif, 94800, France
    Recruiting
  • Helios Klinikum Berlin Buch GmbH Klinik für Gynäkologie und Geburtshilfe
    Berlin, 13125, Germany
    Recruiting
  • Marienhospital Bottrop gGmbH
    Dortmund, 44263, Germany
    Recruiting
  • Universitätsklinikum Carl Gustav Carus an der TU
    Dresden, 01307, Germany
    Recruiting
  • LMU Klinikum - Apotheke
    München, 81377, Germany
    Recruiting
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
    Recruiting
  • Aretaieio Hospital
    Athens, 11528, Greece
    Recruiting
  • Athens Medical Center
    Athens, 15125, Greece
    Recruiting
  • University General Hospital of Patras
    Pátrai, 26504, Greece
    Recruiting
  • European Interbalkan Medical Center
    Thessaloniki, 57001, Greece
    Recruiting

Showing the first 100 of 166 sites across 15 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Apr 2028, 44 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 44 months is close to that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2024
First posted
May 30, 2024
StartActual
Aug 13, 2024
Primary completionEst.
Apr 28, 2028
CompletionEst.
Oct 18, 2030
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06435429
Responsible party
Sponsor
First posted
May 30, 2024
Start date
Aug 13, 2024
Primary completion
Apr 28, 2028 (estimated)
Completion
Oct 18, 2030 (estimated)
Last update
Feb 10, 2026

Study contacts

Clinical Trial Disclosure & Transparency
Contact
ClinicalTrialDisclosure@JazzPharma.com
215-832-3750

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanidatamab

Start the discussion